53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
This ERS 2025 abstract from Hyfe's R&D team validates the wear-detection algorithm built into the Hyfe CoughMonitor smartwatch against participant-reported wear status across 418 person-hours of data in ten participants.
Authored by Hyfe's R&D team, this review synthesizes work presented at the European Respiratory Society Congress 2025 and argues that objective cough monitoring has crossed a practical threshold, moving from experimental technique to deployable clinical endpoint.
This study asked whether the core components of BCST could be embedded in a digital therapeutic and paired with continuous, objective cough monitoring inside the CoughPro app.
01.03.2023
This paper focuses on the potential of using cough frequency as a biomarker for tuberculosis (TB) diagnosis and monitoring treatment response. The study underscores the significance of continuous cough monitoring as a non-invasive method, which could aid in reducing overtreatment in individuals without TB and improve detection in cases missed by standard symptom-based screenings. This approach represents a significant advance in TB management, offering a more precise and patient-friendly diagnostic tool.
The study also highlights the possibility of reducing overtreatment in individuals who do not have TB and emphasizes the importance of innovative digital biomarkers in enhancing TB management, offering a more precise and patient-friendly diagnostic tool.
